IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate platform technologies.
The company has developed a state of the art linker technology comprising of a novel self-immolative group based on Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) chemistry that works with a wide variety of phenolic and non-phenolic payloads. The OPHAS linker was designed to accommodate a wide variety of functional groups and triggering groups. The OHPAS Linker can be triggered by methods that include enzymes (i.e. lysosmal), light, and pH. The resulting ADCs has been shown to be highly stable and have very fast payloads release profiles.
IntoCell has devised other ADC platform technology called Payload Modified Technology (PMT) in which temporary Modifying Group (MG) has been incorporated into traditional payloads. PMT has shown to improve therapeutic index of ADC with significant reduction of normal cell’s uptake, resulting in normal cells being minimally affected.
By utilizing PMT and OHPAS linker technology, IntoCell has successfully delivered a preclinical candidate in the B7-H3 ADC program. ITC-6146RO is the lead candidate that shows high and long-lived potency in a variety of murine xenograft and PDX models with good safety. IND-enabling studies of ITC-6146RO are planned in 2022.